Year: 2016
Type: article
Abstract: prior to 1998 were excluded.Survival was defined as the time from initial biopsy to eGFR < 15mL/min, renal replacement therapy, or death.Immunotherapy (IMT) was defined as any treatment with cyclophosphamide, azathioprine, mycophenolate mofetil, or rituximab.Results: 211 patients had follow-up data (AA=80, W=106, Asian=7, NS=18).African Americans (AA) had a larger proportion of class V LN at presentation (27% vs. 16%, p=0.04).Age, BP, BMI, Diabetes, SCr, 24h protein, C3, C4, ANA, and anti-dsDNA Ab positivity were similar between AA and white patients.Results are mean (SD).Baseline characteristics of other groups were not different (not shown).Overall, AA had shorter survival compared to white patients [HR 1.7, 95% CI: 1.0 to 2.8, p=0.042].Similarly, AA without IMT had shorter survival compared to white patients without IMT [HR 2.2, 95% CI: 1.0 to 4.8, p=0.046].However, AA with IMT did not have different survival compared to white patients with IMT [HR 1.1, 95% CI: 0.5 to 1.1 , p=0.71].Conclusions: Immunotherapy reduces the risk for progression to ESRD and closes the gap in racial disparities between African American and white patients.*=Baseline #=Follow-up Black White *No.Patients (%Female) 94 (84) 132 (80) *Age 35.6 (14) 32.9 (14) *SCr 1.4 (1.2) 1.3 (0.9) *24h Protein 3.9 (2.5) 2.9 (2.4) *ISN/RPS Class II 15 20 III/IV 49 82 III/IV+V 3 8 V 26 22 VI 1 0 #No.Patients with Follow-up 80 106 #Median Follow-up (y) 5.2 7.0 #Median Survival (y) 12.1 16.5 #ESRD or RRT 14 22
Source: Laboratory Investigation
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
OpenAlex ID: W4252117193